Eye drops for optic pathway gliomas: how children were doing four years later
Original title: Long-term outcomes after a randomized phase II trial of nerve growth factor eye drops for optic pathway gliomas: four-year follow-up findings in children.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a follow-up that just watched a small group of children, and the authors say bigger trials are still needed.
The short version
Children who got these eye drops stayed stable for four years, but the study cannot show the drops caused that.
What was studied. This was a follow-up of an earlier trial of nerve growth factor eye drops in children with optic pathway gliomas. Fifteen of the 18 children from that trial were checked for 48 months. Of these, 9 had gotten the drops and 6 had gotten placebo. No one got more drops, chemotherapy, or radiation during this time.
What they found. Doctors checked vision and eye nerve tests every 6 months, and brain MRI every 12 months. Vision, eye nerve test results, and visual field did not change in a meaningful way from start to finish. Brain MRI showed stable disease in all the children.
What this means, and what it doesn't
What it could mean: A short 10 day course of these eye drops looked safe and easy to tolerate over four years. The children's vision and scans stayed steady during that time. That is reassuring, but it is not proof the drops helped.
What it doesn't mean: This does not mean the eye drops work. The authors say these results point to safety, not to lasting benefit. This part of the study just watched children over time, and only 15 children were followed. That is a small group. The authors say larger, well designed trials are still needed. These drops are not standard care, and they are not a cure.
Source: PubMed, September 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.